Affimed Enters into US$5 B Cancer Immunotherapy Collaboration with Genentech
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 9 (Table of Contents)
Published: 11 Sep-2018
DOI: 10.3833/pdr.v2018.i9.2355 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to lead the next generation of cancer therapies, Roche’s Genentech has partnered with Affimed for its ROCK® (Redirected Optimised Cell Killing) platform in a deal worth potentially US$5 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS